Stocklytics Platform
Asset logo for symbol APLS
Apellis Pharmaceuticals
APLS
65
$39.79arrow_drop_up3.56%$1.37

Performance History

Chart placeholder
Key Stats
Open$38.10
Prev. Close$38.07
EPS-3.43
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$4.62B
PE Ratio-
LOWHIGH
Day Range37.43
38.65
52 Week Range19.83
92.61
Ratios
P/B Ratio32.10
Revenue$396.59M
Operating M. %-36.03%
Earnings$0.00
Earnings Growth %18.94%
EBITDA Margin %-101.44%
ROE %-122.94%
EPS-3.43

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$902.79
Perf. (24h)
arrow_drop_up1.42%$12.68
Market Cap$840.04B
Price$484.84
Perf. (24h)
arrow_drop_down1.04%-$5.13
Market Cap$451.00B
Price$147.62
Perf. (24h)
arrow_drop_down1.00%-$1.50
Market Cap$357.99B
Price$133.02
Perf. (24h)
arrow_drop_up0.04%$0.06
Market Cap$331.08B

About Apellis Pharmaceuticals (APLS)

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Cedric Francois M.D., Ph.D.
Headquarters
Waltham
Employees
767
Exchange
NASDAQ
add Apellis Pharmaceuticals  to watchlist

Keep an eye on Apellis Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Apellis Pharmaceuticals 's (APLS) price per share?

The current price per share for Apellis Pharmaceuticals (APLS) is $39.79. The stock has seen a price change of $1.37 recently, indicating a 3.57% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Apellis Pharmaceuticals (APLS)?

For Apellis Pharmaceuticals (APLS), the 52-week high is $92.61, which is 132.75% from the current price. The 52-week low is $19.83, the current price is 100.66% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Apellis Pharmaceuticals (APLS) a growth stock?

Apellis Pharmaceuticals (APLS) has shown an average price growth of 0.41% over the past three years. It has received a score of 76 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Apellis Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Apellis Pharmaceuticals (APLS) stock price performance year to date (YTD)?

As of the latest data, Apellis Pharmaceuticals (APLS) has a year-to-date price change of -35.06%. Over the past month, the stock has experienced a price change of -2.02%. Over the last three months, the change has been -28.35%. Over the past six months, the figure is -33.79%. Looking at a longer horizon, the five-year price change stands at 72.55%.

help
Is Apellis Pharmaceuticals (APLS) a profitable company?

Apellis Pharmaceuticals (APLS) has a net income of -$528.63M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 84.82% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -36.03% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $396.59M, although specific revenue growth data is currently not available. The gross profit is $336.38M. Operating income is noted at -$517.12M. Furthermore, the EBITDA is -$402.32M.

help
What is the market capitalization of Apellis Pharmaceuticals (APLS)?

Apellis Pharmaceuticals (APLS) has a market capitalization of $4.62B. The average daily trading volume is 1.19M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level